Dr. Theodore Moore's research focuses on pediatric hematopoietic stem cell transplantation, specifically stem cell sources and infections in the immunocompromised host. He and his colleagues also are working with acute leukemias and leukemiogenesis, as well as rare pediatric tumors and new drug development.
Shankar DB, Li J, Tapang P, McCall JO, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, Chang JC, Rhodes K, Shah N, Moore TB, Sakamoto KM, Glaser KB, Owen McCall J. ABT-869 a multi-targeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood. 2007.
Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM. FLT3 in Normal Hematopoiesis and Acute Myeloid Leukemia. Stem Cells. 2006.
Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A, Rao NP, Landaw EM, Sakamoto KM. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell. 2005; 7(4): 351-62.
Cheng JC, Moore TB, Sakamoto KM. RNA interference and human disease. Mol Genet Metab. 2003; 80(1-2): 121-8.